Our observations with Compound A’s improvement of abnormal glucose metabolism of 5xFAD mice combined with compelling evidence for PDH activity deficits in AD indicate that this compound may well normalize the impaired glucose metabolism in AD brains as well. The gene discussed is PDP1; the disease is Alzheimer disease.